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Abstract: Mixed tetraoxanes of the 4”-phenyl-substituted cyclohexyl-spirotetraoxacyclo-
hexyl-spirocholate series have been prepared and evaluated as possible antimalarials, anti-
proliferatives and antimycobacterials. The activity of the (4”R or S)-phenyl series against P.
falciparum D6 and W2 strains was found to be at the level of artemisinin, with two com-
pounds, the acid 4 and the amide 6, exhibiting encouraging anti-TB activity as well. Very
promising in vitro results of the said tetraoxanes were obtained against solid tumours and, in
some instances, the activity against a selected number of cell lines was higher than that of the
antitumor drug paclitaxel.
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INTRODUCTION
Malaria, which is caused by multiplication of the protozoan parasite Plasmodium
falciparum in erythrocytes, is a major health problem in many southern countries. The
present resurgence of malaria and the lack of proper treatment effects 300–500 million
people annually causing over 1.5 million deaths.1 More than 400 million disease cases
with over 1.5 million fatalities are the annual toll of P. falciparum infections. The develop-
ment of resistance to the standard antimalarial drug chloroquine (CQ), which had been the
affordable and effective antimalarial mainstay for 50 years, has severe health implications
for countries in malaria endemic regions. In a recent genetic study2 of the malaria parasite,
it is found that this species is unexpectedly diverse; another study3 points to the multiple in-
dependent origins of mutations in one parasite gene that confer resistance to a widely used
drug such as CQ. The results show that, in principle, P. falciparum could rapidly develop
resistance to multiple drugs (CQ: estimated 6–30 years), additionally justifying further
search for new drugs.
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The antimalarial properties of artemisinin4 and of other peroxides such as 1,2,4,5-tetra-
oxacycloalkanes5 against CQ-resistant strains opened a new approach to fighting malaria.
Our research in this area has exploited various steroid derivatives as tetraoxane phar-
macophore carriers: bis-steroidal tetraoxanes,6,7 mixed steroidal tetraoxanes,8 and intra-
molecular tetraoxane9 were explored. Our latest results indicate that cholic acid-based
mixed steroidal tetraoxanes are extremely potent tetraoxane antimalarials in vitro, with the
4”-substituted cyclohexyl-spirotetraoxacyclohexyl-spirocholates appearing to be among
the most potent antimalarials.
Tuberculosis (TB) affects 1.7 billion people per year worldwide, killing ca. 3 mil-
lion.10 It is estimated that about 8 million new cases emerge annually, mostly in sub-Sa-
haran Africa, and the disease, especially targeting people with suppressed immune sys-
tems, e.g., HIV positive cases, is slowly but steadily spreading in the developed countries
as well. Multidrug resistant TB strains have developed,11 and the current lack of new
leads12 additionally warrants the development of new antitubercular drugs.
The toxicity of steroidal tetraoxanes against (PBMC,7 VERO8) as compared to their
antimalarial activity was shown to be low. In addition, preliminary tests on the haemolytic
behaviour of mixed tetraoxanes possessing a C(24) amide terminus revealed no RBC
membrane lysis,8 suggesting that antimalarial activity is the consequence of interaction
specific to infected RBC, and is not the result of uncontrolled RBC membrane lysis.
In this paper, the synthesis and extensive biological evaluation (antimalarial, antitu-
bercular and antiproliferative) of twelve new 4”-phenyl substituted mixed tetraoxanes are
presented.
CHEMISTRY
A bis-dispirotetraoxane compound5b,7 affords little opportunity for selective functi-
onalisation of any incorporated functionality, and such a fact was the motivation to devise a
method for the synthesis of tetraoxanes possessing non-identical spiro substituents at C(3)
and C(6) (“mixed tetraoxanes”).8
In this work, mixed tetraoxanes 2–13were prepared using the same procedure as de-
scribed recently in Ref. 8 (Scheme 1). Gem-dihydroperoxide 1 was treated with prochiral
4-phenylcyclohexanone (Scheme 1) yielding a mixture of tetraoxane diastereomers (2+ 3;
27 %).13 The esters were separated and each was selectively hydrolysed into the corre-
sponding acids 4 and 5. Utilising a mixed anhydride procedure, the acids 4 and 5 were
transformed into amides 6, 8, 10, 12, and 7, 9, 11, 13, respectively. The overall yield of
amides in each series starting from gem-dihydroperoxide 1 was ca. 10 %.
BIOLOGICAL EVALUATION
Antimalarial activity
In vitro antimalarial activity was assessed against two P. falciparum strains: D6 Sierra
Leone clone (CQ and pyrimethamine susceptible, mefloquine resistant), and W2 Indo-
china (CQ and pyrimethamine resistant, mefloquine susceptible). As expected from previ-
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ous findings,6–8 the two diastereomeric series exerted different activity against both strains.
One series (esters, acids, amides), denoted as (4”R or S),13 is ca. 2–8 times more active than
the other one on both strains. While the activity of the (4”S or R) series is in the range of ca.
33 –91 nM, the respective diastereomers (4”R or S) are as active as artemisinin. The esters
show poor activity in comparison to the corresponding amides,7,8 and the acids are usually
the least active in the series.5b,8 However, with the (4”R or S)-phenyl series, Table I, the
unique trend observed with the corresponding (4”R)-methyls and (4”R or S)-ethyls8 is ex-
tended here: the (4”R or S) acid4 is more active than the corresponding ester2, and is as ac-
tive as the corresponding amides 6, 8, 10, 12. The established cytotoxicity against the
VERO cells for compound 4 (IC50 = 1.53 M) provides a good starting SI (IC50 VERO /
IC50 (D6 or W2)) for further improvements of this structure.
Antitubercular activity
All the 4”-phenyl tetraoxanes 2–13 were screened against Mycrobacterium tubercu-
losis, strain H37Rv (Table II), within the NIAID Tuberculosis Antimicrobial Acquisition
and Coordinating Facility program (TAACF).10 Of the 12 compounds screened at level 1,
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Scheme 1.
TABLE I. In vitro antimalarial activity of the tetraoxanes 2 – 13 against P. falciparum D6 and W2 Strains
Compound
(4”R or S)
Compound
(4”S or R)
W D6 (nM) W2 (nM) RI (W2 / D6) W D6 (nM) W2 (nM) RI (W2 / D6)
2 OCH3 17.66 16.48 0.93 3 OCH3 44.67 35.17 0.79
4 OH 8.88 8.74 0.98 5 OH 77.83 62.93 0.80
6 NH2 10.34 10.57 1.02 7 NH2 58.18 53.82 0.92
8 NHMe 12.43 9.80 0.79 9 NHMe 91.02 77.07 0.85
10 NHEt 7.48 8.11 1.08 11 NHEt 45.30 45.00 0.99
12 NHPrn 8.93 9.11 1.02 13 NHPrn 32.90 33.26 1.05
Artemisinin a 8.6 7.3 0.85 Chloroquine b 13.76 185.38 13.47
Artemether a 2.92 1.00 0.34 Mefloquine b 28.29 5.02 0.18
a Taken from Ref. 5c; b Control drugs.
TABLE II. In vitro antimalarial activity of the tetraoxanes 2 – 13 against M. tuberculosis
Compound W Asaay % Inh. MIC (g/mL) Compound W Assay % Inh. MIC (g/mL)
2 OCH3 Alamar 37 > 6.25 3 OCH3 Alamar 46 > 6.25
4 OH Alamar 94 6.25 5 OH Alamar 89 > 6.25
6 NH2 Alamar 93 6.25 7 NH2 Alamar 87 > 6.25
8 NHMe Alamar 71 > 6.25 9 NHMe Alamar 61 > 6.25
10 NHEt Alamar 50 > 6.25 11 NHEt Alamar 62 > 6.25
12 NHPrn Alamar 46 > 6.25 13 NHPrn Alamar 59 > 6.25
Rifampin 0.125 Isoniazid 0.05
two of them (4 and 6) exhibited the required > 90 % inhibition (at the single concentration
of 6.25 g/mL) for entering the next level of screening. The MICs were determined at level
2 of the screening protocol: acid 4 – 6.25 g/mL (94 % inhibition), primary amide 6 – 6.25
g/mL (93 % inhibition). Such high activities of these tetraoxanes indicate that tetraoxanes
might represent a good new anti-TB lead.
Antiproliferative activity
Four of the compounds (2, 4, 6, and 8) were chosen by NIH-NCI for in vitro screen-
ing.14 All the tetraoxanes were evaluated in the 3-cell line (lung – NCI-H460, breast –
MCF7, CNS – SF-268) one dose primary anticancer assay: growth percentage after 48 h,
at a concentration of 100 M of the tested compound. Two compounds were eliminated at
this stage (2 and 8), while the acid 4 and primary amide 6 were evaluated against the full
panel of 60 human tumor cell lines starting at a concentation of 10–4 M of the investigated
compound. The assessed antiproliferative activity, expressed as GI50, TGI, LC50 were ob-
tained applying the 48 h continuous drug exposure protocol using the SRB (sulfor-
hodamine B) protein assay.14 The results, given in Table III, indicate that both compounds
are strong antiproliferatives with 50 % growth inhibitory activities (GI50), often at the
nanomolar concentration. The highest activity was exhibited by the primary amide 6 on a
melanoma cancer cell line (MALME-3M; GI50 = 20 nM). The compounds arrested the
cancer cells growth (TGI) at concentrations within the ca. 0.8 – 6 M range, with the acid4
being a good inhibitor of the growth of the ovarian cancer cell line (IGROV1; TGI = 0.82
M). The LC50 values (concentration of the compound at which 50 % of the cells are
killed) for both compounds are mostly at the 10–6 M level indicating, together with previ-
ous results,7 that steroidal tetraoxanes are possibly good new leads in fighting cancer. For
comparison, the corresponding inhibitory activity of the antimalarial artemisinin and the
antitumor drug paclitaxel are also given in Table III.
TABLE III. In vitro antiproliferative activity of tetraoxanes 4 and 6 (after 48 h, M; selected data)
Cell Line
Artemisinin
(NSC 369397)
Comp. 4 Comp. 6
Paclitaxel
(NSC 125973)
IGROV1a
GI50
TGI
LC50
79.4
100
100
0.26
0.82
3.76
0.295
1.11
–
0.032
79.4
100
TK-10b
GI50
TGI
LC50
100
100
100
1.99
5.94
27.0
2.70
4.66
8.07
0.25
50.1
79.4
UO-31b
GI50
TGI
LC50
79.4
100
100
1.83
3.51
6.73
0.36
1.35
4.57
1.58
39.8
100
SRc
GI50
TGI
LC50
100
100
100
1.83
5.92
100
0.29
–
100
0.079
63.1
63.1
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Cell Line
Artemisinin
(NSC 369397)
Comp. 4 Comp. 6
Paclitaxel
(NSC 125973)
KM-12d
GI50
TGI
LC50
100
100
100
1.96
5.36
40.1
1.19
2.92
7.15
0.0079
79.4
100
MALME-3Me
GI50
TGI
LC50
100
100
100
2.27
9.14
47.0
0.020
3.99
37.3
2.51
50.1
79.4
a Ovarian cancer cell line; b Renal cancer cell line; c Leukemia cell line; d Colon cancer cell line; e Melanoma
cancer cell line.
DISCUSSION
In this paper, the synthesis and the activity of two diastereomeric series of 4”-phenyl
mixed tetraoxanes are reported. The antimalarial activity of one series, designated as (4”R
or S), is significantly higher than that of the corresponding C(4”) epimeric series, and is at
the level of the proto peroxide antimalarial artemisinin (Table I). All members of the (4”R
or S) series are almost equally active against both the P. falciparum strains tested, D6 and
W2, and the determined cytotoxicity of tetraoxane4 (IC50= 1.53 M) against VERO cells,
affords solid ground for further development of these compounds as antimalarials.
In Table III, the selected antiproliferative activity data of compounds 4 and 6 are com-
pared to these of artemisinin (NSC 369397) and the antitumor drug paclitaxel (NSC
125973). While artemisinin is ineffective as an antiproliferative, our compounds exhibit
significant activity against various solid cancer types in vitro. The previously observed7
pronounced activity (GI50, TGI, LC50) of bis-steroidal tetraoxanes against renal cancers is
confirmed here, with both the acid 4 and the primary amide 6 being more active than
paclitaxel on the TK-10 and UO-31 renal cancer cell lines. The acid4was found to be most
active against the ovarian IGROV1 cell line, while the amide 6was most active against the
melanoma MALME-3M cell line.***
To conclude, mixed tetraoxanes of the 4”-phenyl series have been prepared and eval-
uated as possible antimalarials, cancer antiproliferatives and antimycobacterials. The activ-
ity of the (4”R or S)-phenyl series against the primary target of this investigation, P.
falciparum D6 and W2 strains, was found to be at the level of artemisinin, with two com-
pounds, the acid 4 and the amide 6, exhibiting encouraging anti-TB activity as well. Very
promising in vitro results of the above cited tetraoxanes were obtained against solid tu-
mours and, in some instances, the activity against a selected number of cell line was higher
than that of the antitumor drug paclitaxel.
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EXPERIMENTAL
General
Melting points were determined on Boetius PMHK apparatus and were not corrected. Specific rotations
were determined on a Perkin-Elmer 141-MC at the given temperatures. IR spectra were recorded on a
Perkin-Elmer spectrophotometer FT-IR 1725X. 1H- and 13C-NMR spectra were recorded on a Varian Gem-
ini-200 spectrometer (at 200 and 50 MHz, respectively) in the indicated solvent using TMS as the internal
standard. Chemical shifts are expressed in ppm () values and coupling constants (J) in Hz. Thin-layer chro-
matography (TLC) was performed on precoated Merck silica gel 60 F254 plates, using N,N-dimethyl-p-phe-
nylene-diammonium dichloride peroxide reagent for the detection of peroxide moieties,15 and Lobar
LichroPrep Si 60 (40–63 m) columns coupled to a Waters RI 401 detector were used for column chromatog-
raphy. Where appropriate, the compounds are listed according to their elution order.
Methyl 3,3-dihydroperoxy-7,12-diacetoxy-5-cholan-24-oate (1)
Gem-dihydroperoxide 1 was synthesized according to procedure described in Ref. 8.
Methyl 7,12-diacetoxy-5-cholan-24-oate-3-spiro-6’-(1’,2’,4’,5’-tetraoxacyclohexane)-3’-spiro-1”- ((4”R
or S)- and (4”S or R)-phenyl)cyclohexane (2 and 3)
A solution of the dihydroperoxide 1 (500 mg, 0.90 mmol) in CH2Cl2 (14 mL) and 4-phenyl-
cyclohexanone (314 mg, 1.80 mmol) at r.t. was cooled with stirring in an ice-bath. After 30 min, 0.6 mL of an
ice-bath cooled (H2SO4 : CH3CN)-mixture (1:10, v/v) was added dropwise. The reaction mixture was stirred
at 0 ºC for 15 min and, after the usual work-up,7 the crude product was purified by column chromatography
(Lobar B, LichroPrep Si 60, eluent heptane / EtOAc (85:15); Lobar B, LichroPrep RP-8, eluent MeOH / H2O
(9:1)) to afford the tetraoxanes 2 and 3.
2 (4”R or S): Yield 96 mg (15 %). Colourless foam, softens at 101–104 ºC. 20D = +34.27 (c =1.14,
CHCl3). IR (KBr): 2945 m, 2875 m, 1737 s, 1449 m, 1378 m, 1248 s, 1072 m, 1030 m, 945 w, 938 w cm
-1.
1H-NMR (200 MHz, CDCl3): 7.40–7.10 (m, Ph–C(4”)), 5.10 (bs, H–C(12)), 4.93 (bs, H–C(7)), 3.66 (s,
CH3O2C(24)), 2.12 (bs, CH3COO–), 2.10 (bs, CH3COO–), 0.95 (s, H3C–C(10)), 0.82 (d, J = 6.0 Hz
H3C–C(20)), 0.74 (s, H3C–C(13)).
13C-NMR (50 MHz, CDCl3): 174.53, 170.54, 145.74, 128.43, 126.76,
126.28, 108.65, 107.83, 75.24, 70.65, 51.48, 47.29, 44.99, 43.43, 43.26, 37.63, 34.63, 34.53, 30.81, 30.68,
29.57, 28.36, 27.10, 25.64, 22.75, 22.05, 21.58, 21.32, 17.45, 12.15. Anal. Calcd. for C41H58O10·0.5 H2O
(719.92): C 68.40, H 8.26; Found: C 68.60, H 8.30. 3 (4”S or R): Yield 77 mg (12 %). Colourless foam, soft-
ens at 186–190 ºC. 20D = +47.67 (c = 1.03, CHCl3). IR (KBr): 2951 m, 2880 m, 1738 s, 1449 m, 1378 m,
1253 s, 1128 w, 1062 w, 1025 w, 970 w, 932 w cm-1. 1H-NMR (200 MHz, CDCl3): 7.40–7.20 (m, Ph–C(4”)),
5.09 (bs, H–C(12)), 4.93 (bs, H–C(7)), 3.66 (s, CH3O2C(24)), 2.13 (bs, CH3COO–), 2.08 (bs, CH3COO–),
0.96 (s, H3C–C(10)), 0.81 (d, J = 6.0 Hz H3C–C(20)), 0.74 (s, H3C–C(13)).
13C-NMR (50 MHz, CDCl3):
174.53, 170.60, 145.73, 128.42, 126.79, 126.28, 108.66, 107.87, 75.25, 70.64, 51.48, 47.30, 45.02, 43.56,
43.30, 37.62, 34.66, 34.53, 30.81, 30.69, 29.53, 28.42, 27.10, 25.69, 22.73, 22.06, 21.38, 17.44, 12.17. Anal.
Calcd. for C14H58O10 (710.91): C 69.27, H 8.22; Found: C 68.93, H 7.89.
7,12-Diacetoxy-5-cholan-24-oic acid-3-spiro-6’-(1’,2’,4’,5’-tetraoxacyclohexane)-3’-spiro-1”-((4”R or
S)-phenyl)cyclohexane (4)
Methyl ester 2 (250 mg, 0.35 mmol) was hydrolysed at 90 ºC with NaOH (21.1 mg, 0.53 mmol) in
i-PrOH / H2O mixture (10 mL, 3:1 v/v). After 30 min, reaction mixture was cooled and diluted with 10 mL
H2O and 30 mLCH2Cl2. The aqueous layer was acidified to pH 2 with diluted HCl, and the layers were sepa-
rated. The aqueous layer was further extracted with CH2Cl2 (320 mL). The combined organic layers were
washed with water and brine, dried over anh. Na2SO4 and evaporated to dryness. Acid 4: yield 215 mg (88
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%), colourless foam softens at 139 – 143 ºC. 20D = +32.48 (c = 1.10, CHCl3). IR (KBr): 3419 w, 2945 m,
2880 w, 1738 s, 1449 w, 1383 m, 1247 s, 1123 w, 1079 w, 1030 w, 970 w, 932 w cm–1. 1H-NMR (200 MHz,
CDCl3): 7.40–7.10 (m, Ph–C(4”)), 5.10 (bs, H–C(12)), 4.93 (bs, H–C(7)), 2.13 (bs, CH3COO–), 0.96 (s,
H3C–C(10)), 0.83 (d, J = 4.6 Hz, H3C–C(20)), 0.74 (s, H3C–C(13)).
13C-NMR (50 MHz, CDCl3): 170.62,
145.72, 128.42, 126.75, 126.28, 108.64, 107.84, 75.24, 70.68, 47.23, 44.98, 43.41, 37.59, 34.61, 34.46, 30.45,
29.56, 28.34, 27.05, 25.62, 24.49, 22.71, 22.04, 21.58, 21.33, 17.42, 12.16. Anal. Calcd. for C40H56O10· H2O
(714.90): C 67.20, H 8.18; Found: C 67.23, H 8.31.
7,12-Diacetoxy-5-cholan-24-oic acid-3-spiro-6’-(1’,2’,4’,5’-tetraoxacyclohexane)-3’-spiro-1”-((4”S or
R)-phenyl)cyclohexane (5)
Methyl ester 3 (250 mg, 0.35 mmol) was hydrolysed using the same procedure as given above for the
preparation of 4.
Acid 5: yield 229 mg (93 %), colorless foam softens at 137–140 ºC. 20D = +43.87 (c = 1.06, CHCl3).
IR (film): 3436 s, 2946 w, 1739 m, 1642 m, 1448 w, 1378 w, 1244 m, 1131 w, 1061 w, 1033 w cm-1. 1H-NMR
(200 MHz, CDCl3): 7.40–7.10 (m, Ph–C(4”)), 5.10 (bs, H–C(12)), 4.93 (bs, H–C(7)), 2.14 (bs, CH3COO–),
2.09 (bs, CH3COO–), 0.96 (s, H3C–C(10)), 0.82 (d, J = 5.6 Hz, H3C–C(20)), 0.74 (s, H3C–C(13)).
13C-NMR
(50 MHz, CDCl3): 179.78, 170.68, 145.72, 128.42, 126.78, 126.28, 108.65, 107.88, 75.26, 70.68, 47.26,
45.02, 43.54, 43.28, 37.60, 34.65, 34.46, 30.45, 29.53, 28.39, 27.07, 25.69, 22.71, 22.05, 21.59, 21.40, 17.41,
12.18. Anal. Calcd. for C40H56H10·0.5H2O (705.90): C 68.06, H 8.14; Found: C 67.97, H 7.83.
General procedure for the preparation of the amides 6–13
Asolution of 4 (263.4 mg, 0.38 mmol), in dry CH2Cl2 (20 mL), with added Et3N (52.9 L, 0.38 mmol)
and ClCO2Et (36.31 L, 0.5 mmol) was stirred for 60 min at 0 ºC. Given amount of amine given below was
added, and after 30 min of stirring the reaction mixture was warmed to r.t. After 90 min it was diluted with
H2O, the layers were separated and the reaction mixture was worked-up in the usual manner.
7 The crude
product was purified by column chromatography.
7,12-Diacetoxy-5-cholan-24-amide-3-spiro-6’-(1’,2’,4',5’-tetraoxacyclohexane)-3’-spiro-1”-((4”R or S)-phe-
nyl)cyclohexane (6)
Using a suspension of 10 eq. NH4Cl and 10 eq. Et3N in dry CH2Cl2 (20 mL), 209 mg (79 %) of 6were
obtained. Column chromatography: eluent EtOAc. Colourles foam softens at 142–146 ºC. 20D = +35.79 (c
= 1.08, CHCl3). IR (KBr): 3458 m, 2946 s, 2876 m, 1739 s, 1675 m, 1621 w, 1448 m, 1378 m, 1243 s, 1131 w,
1082 m, 1034 m, 969 w, 937 w cm-1. 1H-NMR (200 MHz, CDCl3): 7.40–7.00 (m, Ph–C(4”)), 5.80–5.40 (m,
H2N–C(24)), 5.10 (bs, H–C(12)), 4.93 (bs, H–C(7)), 2.12 (bs, CH3COO–), 2.10 (bs, CH3COO–), 0.95 (s,
H3C–C(10)), 0.83 (d, J = 5.6 Hz, H3C–C(20)), 0.74 (s, H3C–C(13)).
13C-NMR (50 MHz, CDCl3): 175.90,
170.57, 145.72, 128.43, 126.75, 126.28, 108.63, 107.83, 75.24, 70.65, 47.40, 45.01, 43.41, 43.23, 37.60,
34.61, 32.66, 31.29, 29.59, 28.34, 27.14, 25.64, 22.73, 22.04, 21.58, 21.34, 17.53, 12.18. Anal. Calcd. for
C40H57NO9 ·	
 2O (704.91): C 68.16, H 8.29; Found: C 68.09, H 8.22.
N-Methyl-7,12-diacetoxy-5-cholan-24-amide-3-spiro-6’-(1’,2’,4’,5'-tetraoxacyclohexane)-3’-
spiro-1"-((4”R or S)-phenyl)cyclohexane (8)
Acid 4 (263.7 mg, 0.38 mmol) was transformed into 8 (210 mg, 78 %) according to the general proce-
dure using a suspension of 6 eq. MeNH3Cl / 6 eq. Et3N in 20 ml dry CH2Cl2. Column chromatography: Lobar
B, LichroPrep Si 60; eluent EtOAc. Colourless foam softens at 133–137 ºC. 20D = +28.03 (c = 1.09,
CHCl3). IR (KBr): 3353 w, 2945 s, 2880 w, 1738 s, 1656 m, 1553 w, 1455 w, 1378 m, 1253 s, 1128 w, 1079 w,
1030 m, 965 w, 943 w cm-1. 1H-NMR (200 MHz, CDCl3): 7.40–7.10 (m, Ph–C(4”)), 5.60–5.40 (m,
HN–C(24)), 5.10 (bs, H–C(12)), 4.92 (bs, H–C(7)), 2.80 (d, J = 4.80 Hz, H3C–NH), 2.12 (bs, CH3COO–),
0.95 (s, H3C–C(10)), 0.82 (d, J = 5.80 Hz, H3C–C(20)), 0.73 (s, H3C–C(13)).
13C-NMR (50 MHz, CDCl3):
173.93, 170.58, 145.71, 128.42, 126.74, 126.26, 108.62, 107.82, 75.25, 70.64, 47.42, 44.98, 43.40, 43.21,
37.59, 34.69, 34.60, 33.35, 31.47, 30.54, 29.55, 28.34, 27.12, 26.25, 25.62, 22.72, 22.04, 21.58, 21.33, 17.52,
12.17. Anal. Calcd. for C41H59NO9· 0.5 H2O (718.94): C 68.50, H 8.41; Found: C 68.84, H 8.71.
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N-Ethyl-7,12-diacetoxy-5-cholan-24-amide-3-spiro-6’-(1’,2’,4’,5'-tetraoxacyclohexane)-3’-spiro-1”-((4”R
or S)-phenyl)cyclohexane (10)
Acid 4 (261.3 mg, 0.37 mmol) was transformed into 10 (216 mg, 80 %) according to the general proce-
dure using a suspension of 6 eq. EtHN3Cl / 6 eq. Et3N in 20 ml dry CH2Cl2. Column chromatography: Lobar
B, LichroPrep Si 60; eluent EtOAc / heptane (95/5). Colourless foam, softens at 128–131 ºC. 20D = +34.36
(c = 1.04, CHCl3). IR (KBr): 3326 w, 2951 m, 2880 m, 1738 s, 1656 m, 1547 w, 1455 m, 1379 m, 1248 s, 1128
w, 1085 w, 1030 m, 965 w, 938 w cm-1. 1H-NMR (200 MHz, CDCl3): 7.40–7.10 (m, Ph–C(4”)), 5.60–5.40
(m, HN–C(24)), 5.10 (bs, H–C(12)), 4.92 (bs, H–C(7)), 3.40–3.10 (m, CH3CH2–NH–), 2.12 (bs, CH3COO–),
2.09 (bs, CH3COO–), 1.13 (t, J = 7.2 Hz, CH3CH2–NH–), 0.95 (s, H3C–C(10)), 0.82 (d, J = 6 Hz,
H3C–C(20)), 0.73 (s, H3C–C(13)).
13C-NMR (50 MHz, CDCl3): 173.11, 170.58, 145.72, 128.42, 126.74,
126.28, 108.63, 107.82, 75.25, 70.63, 47.42, 44.98, 43.40, 43.22, 37.58, 34.67, 34.60, 34.25, 33.49, 31.48,
30.53, 29.43, 28.34, 27.12, 25.61, 22.71, 22.04, 21.56, 21.33, 17.54, 14.83, 12.16. Anal. Calcd. for
C42H61NO9·0.5 H2O (732.96): C 68.83, H 8.53; Found: C 68.81, H 8.57.
N-(n-Propyl) -7,12-diacetoxy-5-cholan-24-amide-3-spiro-6’-(1’,2’,4’,5'-tetraoxacyclohexane)-3’-spiro-1”- ((4”
R or S)-phenyl)cyclohexane (12)
Acid 4 (259.2 mg, 0.37 mmol) was transformed into 12 (210 mg, 76 %) according to the general proce-
dure using 60.24 L, (0.74 mmol) n-PrNH2. Column chromatography: Lobar B, LichroPrep Si 60; eluent
EtOAc / heptane (95/5). Colourless foam, softens at 125–127 ºC. 20D = +32.25 (c = 1.10, CHCl3). IR
(KBr): 3413 w, 3326 w, 2945 s, 2875 m, 1738 s, 1656 m, 1547 w, 1455 m, 1378 m, 1248 s, 1128 w, 1078 m,
1030 m, 965 w, 943 w cm-1. 1H-NMR (200 MHz, CDCl3): 7.40–7.10 (m, Ph–C(4”)), 5.60–5.40 (m,
HN–C(24)), 5.10 (bs, H–C(12)), 4.93 (bs, H–C(7)), 3.40–3.10 (m, CH3CH2CH2–NH–), 2.12 (bs,
CH3COO–), 1.70–1.20 (m, CH3CH2CH2–NH–), 1.00–0.80 (m, H3C–C(10), CH3CH2CH2–NH–), 0.82 (d, J
= 6.0 Hz, H3C–C(20)), 0.73 (s, H3C–C(13)).
13C-NMR (50 MHz, CDCl3): 173.21, 170.59, 145.73, 128.43,
126.76, 126.28, 108.64, 107.83, 75.27, 70.65, 47.45, 44.99, 43.41, 43.23, 41.13, 37.59, 34.61, 33.55, 31.54,
29.55, 28.34, 27.13, 25.62, 22.83, 22.04, 21.57, 21.34, 17.54, 12.17, 11.30. Anal. Calcd. for C43H63NO9·0.5
H2O (746.99): C 69.14, H 8.64; Found: C 68.94, H 8.85.
7,12-Diacetoxy-5-cholan-24-amide-3-spiro-6’-(1’,2’,4’,5'-tetraoxacyclohexane)-3’-spiro-1”-
((4" S or R)-phenyl)cyclohexane (7)
Acid 5, (273.5 mg, 0.39 mmol) was transformed into 7 (236 mg, 86 %) using a suspension of 10 eq.
NH4Cl / 10 eq. Et3N in 20 ml dry CH2Cl2. Column chromatography: Lobar B, LichroPrep Si 60; eluent
EtOAc. Colourless foam, softens at 141–144 ºC. 20D = +41.37 (c = 1.02, CHCl3). IR (KBr): 3463 w, 3356
w, 2952 m, 2876 m, 1739 s, 1675 m, 1621 w, 1448 m, 1384 m, 1249 s, 1131 w, 1061 w, 1028 m, 969 w, 942 w
cm-1. 1H-NMR (200 MHz, CDCl3): 7.40–7.10 (m, Ph–C(4”)), 5.70–5.30 (m, H2N–C(24)), 5.13 (bs,
H–C(12)), 4.95 (bs, H–C(7)), 2.16 (bs, CH3COO–), 2.12 (bs, CH3COO–), 0.99 (s, H3C–(10)), 0.86 (d, J = 5.8
Hz, H3C–C(20)), 0.77 (s, H3C–C(13)).
13C-NMR (50 MHz, CDCl3): 175.83, 170.63, 145.74, 128.43, 126.80,
126.29, 108.66, 107.89, 75.28, 70.66, 47.43, 45.06, 43.56, 43.30, 37.63, 34.67, 32.70, 31.31, 29.56, 28.42,
27.15, 25.71, 22.75, 22.06, 21.59, 21.43, 17.55, 12.21. Anal. Calcd. for C40H57NO9·0.5 H2O (704.91): C
68.16, H 8.29; Found: C 68.27, H 8.57.
N-Methyl-7,12-diacetoxy-5-cholan-24-amide-3-spiro-6’-(1’,2’,4’,5'-tetraoxacyclohexane)-3’-spiro-1”-
((4”S or R)-phenyl)cyclohexane (9)
Acid 5 (256.7 mg, 0.37 mmol) was transformed into 9 (217 mg, 83 %) according to the general proce-
dure using a suspension of 6 eq. MeNH3Cl / 6 eq. Et3N in 20 ml dry CH2Cl2. Column chromatography: Lobar
B, LichroPrep Si 60; eluent EtOAc. Colourless foam, softens at 137–140 ºC. 20D = +47.15 (c = 0.90,
CHCl3). IR (KBr): 3402 w, 3343 w, 2945 s, 2875 m, 1738 s, 1661 m, 1553 w, 1449 m, 1378 m, 1248 s, 1169 w,
1128 w, 1063 m, 1030 m, 970 w, 938 w cm-1. 1H-NMR (200 MHz, CDCl3): 7.40–7.10 (m, Ph–C(4”)),
5.60–5.30 (m, HN–C(24)), 5.09 (bs, N–C(12)), 4.92 (bs, H–C(7)), 2.80 (d, J = 5.0 Hz, H3C–NH), 2.13 (bs,
CH3COO–), 2.08 (bs, CH3COO–), 0.96 (s, H3C–C(10)), 0.81 (d, J = 6.0 Hz, H3C–C(20)), 0.73 (s,
H3C–C(13)).
13C-NMR (50 MHz, CDCl3): 173.90, 170.63, 145.74, 128.43, 126.79, 126.28, 108.67, 107.88,
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75.29, 70.65, 47.47, 45.04, 43.56, 43.29, 37.63, 34.67, 33.39, 31.50, 30.58, 29.60, 28.42, 27.13, 26.27, 25.70,
22.75, 22.06, 21.59, 21.41, 17.55, 12.21. Anal. Calcd. for C41H59NO9·0.5 H2O (718.94): C 68.50, H 8.41;
Found: C 68.69, H 8.30.
N-Ethyl-7,12-diacetoxy-5-cholan-24-amide-3-spiro-6’-(1’,2’,4’,5'-tetraoxacyclohexane)-3’-spiro-1”-((4”
S or R)-phenyl)cyclohexane (11)
Acid 5 (256.5 mg, 0.37 mmol) was transformed into 11 (224 mg, 84 %) according to the general proce-
dure using a suspension of 6 eq. EtNH3Cl / 6 eq. Et3N in 20 ml dry CH2Cl2. Column chromatography: Lobar
B, LichroPrep Si 60; eluent EtOAc / heptane (95/5). Colourless foam, softens at 129–132 ºC. 20D = +46.12
(c = 0.97, CHCl3). IR (KBr): 3440 m, 2951 s, 2880 m, 1738 s, 1655 m, 1547 w, 1449 m, 1378 m, 1248 s, 1128
w, 1063 w, 1030 m, 970 w, 943 w cm-1. 1H-NMR (200 MHz, CDCl3): 7.40–7.10 (m, Ph–C(4”)), 5.60–5.40
(m, HN–C(24)), 5.10 (bs, H–C(12)), 4.92 (bs, H–C(7)), 3.40–3.10 (m, CH3CH2–NH–), 2.13 (bs, CH3COO–),
2.09 (bs, CH3COO–), 1.30–1.10 (m, CH3CH2–NH–), 0.96 (s, H3C–C(10)), 0.82 (d, J = 5.8 Hz, H3C–C(20)),
0.73 (s, H3C–C(13)).
13C-NMR (50 MHz, CDCl3): 173.15, 170.60, 170.40, 145.69, 128.39, 126.76, 126.25,
108.62, 107.84, 75.26, 70.62, 47.42, 45.00, 43.51, 43.26, 37.58, 34.63, 34.24, 33.49, 31.48, 30.53, 29.48,
28.38, 27.11, 25.67, 22.70, 22.03, 21.54, 21.38, 17.53, 14.82, 12.17. Anal. Calcd. for C42H61NO9·0.5 H2O
(732.96): C 68.83, H 8.53; Found: C 68.70, H 8.89.
N-(n-Propyl)-7,12-diacetoxy-5-cholan-24-amide-3-spiro-6’-(1’,2’,4’,5'-tetraoxacyclohexane)-3’-spiro-
1”-((4”S or R)-phenyl)cyclohexane (13)
Acid 5 (258.1 mg, 0.37 mmol) was transformed into 13 (214 mg, 78 %) according to the general proce-
dure using 59.92 L (0.74 mmol) n-PrNH2. Column chromatography: Lobar B, LichroPrep Si 60; eluent
EtOAc / heptane (95/5). Colourless foam, softens at 127–131 ºC. 20D = +45.23 (c = 1.07, CHCl3). IR
(KBr): 3402 w, 3321 w, 2945 s, 2880 m, 1738 s, 1656 m, 1547 w, 1449 m, 1378 m, 1248 s, 1128 w, 1063 w,
1030 m, 970 w, 938 w cm-1. 1H-NMR (200 MHz, CDCl3): 7.40–7.10 (m, Ph–C(4”)), 5.50–5.30 (m,
HN–C(24)), 5.10 (bs, H–C(12)), 4.92 (bs, H–C(7)), 3.40–3.10 (m, CH3CH2CH2–NH–), 2.13 (bs, CHCOO–),
2.08 (bs, CH3COO–), 1.70–1.30 (m, CH3CH2CH2–NH–), 1.00–0.80 (m, H3C–C(10), CH3CH2CH2–NH–),
0.82 (d, J = 6.0 Hz, H3C–C(20)), 0.73 (s, H3C–C(13)).
13C-NMR (50 MHz, CDCl3): 173.21, 170.62, 145.73,
128.42, 126.78, 126.28, 108.65, 107.87, 75.29, 70.64, 47.47, 45.03, 43.55, 43.28, 41.13, 37.61, 34.66, 33.58,
31.56, 29.53, 28.41, 27.13, 25.70, 22.85, 22.05, 21.57, 21.41, 17.55, 12.20, 11.30. Anal. Calcd. for
C43H63NO9 (737.98): C 69.99, H 8.60; Found: C 70.03, H 8.88.
IZVOD
ANTIMALARIJSKA,ANTIMIKOBAKTERIJSKAIANTIPROLIFERATIVNA
AKTIVNOSTFENIL-SUPSTITUISANIHTETRAOKSANA
DEJANOPSENICA1,DENNIS E. KYLE2, WILBUR K MILHOUS2 i BOGDANA.[OLAJA3
1Institut za hemiju, tehnologiju i metalurgiju, Beograd, 2Division of Experimental Therapeutics, Walter Reed Army Insti-
tute of Research, Washington, DC 20307-5100, USA i 3Hemijskifakultet, Univerzitet uBeogradu, p. pr. 158, Beograd
U ovom radu prikazana je sinteza serije me{ovitih tetraoksana, 4”-fenil-supstitui-
sanih cikloheksil-spirotetraoksacikloheksil-spiroholata, a ispitana je i wihova in vitro
aktivnost kao mogu}ih antimalarika, anti-TBC agenasa i antiproliferativnih jediwewa.
Aktivnost (4”R ili S)-fenil serije naD6 iW2 sojeve P. falciparum vrlo je sli~na aktivnosti
poznatog antimalarika artemizinina. Izra`enu anti-TBC aktivnost iskazala su jediwewa
4 i 6, ~ija antiproliferativna in vitro aktivnost prema nekim kompaktnim tumorima pre-
vazilazi aktivnost leka paklitaksela.
(Primqeno 10. novembra 2002)
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